Mr Smith is a Biotech/Pharmaceutical Executive, Board Director and Clinical/Scientific Advisor in the US, Europe, Canada and Australia. Her experience covers 50+ clinical trials and 20+ major regulatory approvals in multiple jurisdictions including FDA (USA), EMA (Europe), TGA (Australia), ANVISA (Brazil), and PMDA (Japan); leading to product launches across therapeutic areas including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox, Aczone), neuroscience (Abilify, Solriamfetol), and anti-infectives (Teflaro). In addition to growth and creation of R&D pipelines, Dr Smith's record of business development includes acquisitions, divestitures, and partnership deals. Dr. Smith has held executive roles over the past 20 years, including President, CEO, Global Head of R&D, and Chief Medical Officer. She has built companies from the ground up and is advocate for women in science and diversity in the Boardroom. Earlier in her career, she held senior leadership roles at Allergan, AstraZeneca and Bristol Myers Squibb. Dr. Smith serves on the board of Sangamo Therapeutics (SGMO), Talaris Therapeutics (TALS), and Capstan Therapeutics. Previously, Dr. Smith served on the board of Forward Pharma, Sucampo Pharma, Acceleron Pharma, and Antares Pharma, each with a corporate exit through acquisition. Dr. Smith also holds British and Australian citizenships and is a US Permanent Resident.
